Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present invention relates to a method of producing ginsenoside 20(S)—Rg3 or 20(S)—Rh2 using a novel ginsenoside glycosidase in order to obtain ginsenoside 20(S)—Rg3 or 20(S)—Rh2 with high efficiency and high purity. According to the production method of the present invention, a large amount of 20(S)—Rg3 or 20(S)—Rh2, which is a minor form of rare ginsenoside present in very small amounts in ginseng or processed ginseng products, may be safely and efficiently produced. In particular, the method according to the present invention has an advantage in that it may produce a large amount of 20(S)—Rg3 or 20(S)—Rh2 for industrial applications, since the process is very simple and the production efficiency is very high.

Abstract: The present invention relates to a method of producing ginsenoside 20(S)—Rg3 or 20(S)—Rh2 using a novel ginsenoside glycosidase in order to obtain ginsenoside 20(S)—Rg3 or 20(S)—Rh2 with high efficiency and high purity. According to the production method of the present invention, a large amount of 20(S)—Rg3 or 20(S)—Rh2, which is a minor form of rare ginsenoside present in very small amounts in ginseng or processed ginseng products, may be safely and efficiently produced. In particular, the method according to the present invention has an advantag5e in that it may produce a large amount of 20(S)—Rg3 or 20(S)—Rh2 for industrial applications, since the process is very simple and the production efficiency is very high.

Abstract: The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition.

Abstract: The present invention generally relates to novel compounds HNP-98701A (epi-manassantin A), HNP-98701B and HNP-98701C (manassantin A), or mixture thereof (HNP-98701) as carcinostatis substance, preparation method thereof and carcinostatis pharmaceutical composition containing them as effective constituents and, more specifically, to novel compounds HNP-98701A and HNP-98701B, known compounds HNP-98701C, or mixture thereof and derivatives thereof obtained by extracting saururus with methanol, fractionating this with various organic solvents, separating ethyl acetate fraction with highest anticancer activity through thin-layer chromatography or column chromatography and purifying it, preparation method thereof and carcinostatis pharmaceutical composition containing them as effective constituents. The carcinostatis substances HNP-98701A, HNP-98701B and HNP-98701C of the present invention selectively affect cancer cell line cells and cause apoptosis-type cell death.